COVID-19 infection
Conditions
Interventions
treatment group:Shenqi Baofei prescription or Shenmai Baofei prescription
control group:Shenqi Baofei prescription placebo or Shenmai Baofei prescription placebo
Sponsors
The First Affiliated Hospital of Henan University of Chinese Medicine
Eligibility
Sex/Gender
All
Age
65 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Elderly patients with COVID-19 infection (medium/severe/critical type) who meet the diagnostic criteria and classification within 1 week after discharge; 2. It is consistent with the syndrome differentiation of Qi deficiency and phlegm-dampness (lung qi deficiency, phlegm-dampness not exhausted), Qi Yin deficiency and phlegm-heat syndrome (Qi Yin deficiency, phlegm-heat not clear); 3. Aged >= 65 years; 4. At least one or more symptoms (cough, phlegm, fever, conscious fever, shortness of breath/dyspnea, chest pain, headache, palpitation, fatigue/fatigue, sleep disorders, cognitive dysfunction, activity restriction, reduced taste/loss, decreased smell/loss, poor appetite, diarrhea, etc.) were reported within 12 hours before screening. 5. Pulmonary CT imaging is not completely absorbed; 6. Voluntary treatment and oral medication; 7. Sign the informed consent form.
Exclusion criteria
Exclusion criteria: 1. Delirious, consciousness disorder, dementia, various mental patients; 2. Patients with infectious diseases such as bronchiectasis, active pulmonary tuberculosis or lung abscess; 3. Patients with neuromuscular diseases associated with aspiration risk and long-term bed rest; 4. Tumor patients who have received radiotherapy and chemotherapy, targeted, immune, antivascular therapy in the past 6 months; 5. Patients with severe cardiovascular disease (acute myocardial infarction, grade 3 or above cardiac function) and severe liver and kidney disease (severe liver disease refers to bleeding from cirrhosis, portal hypertension and varicose veins, severe kidney disease including dialysis and kidney transplantation); 6. People who are participating in clinical trials of other drugs, who are known to be allergic to the treatment, and who are not considered suitable for inclusion by the researchers.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Readmission rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| mortality;Clinical symptom score;dyspnea scores;6 minutes' walk distance;Pulmonary Function Testing;Chest CT imaging;SF-36, Medical Outcomes Study 36-item Short Form Health Survey;Patient Health Questionnaire-9 (PHQ-9);7 items of General Anxiety Disorder (GAD-7); Pittsburghsleepqualityindex;The post-traumatic stress disorder cheeklist (PCL-C);Safety observation index; | — |
Countries
China
Contacts
Public ContactLi Jiansheng
The First Affiliated Hospital of He'nan University of Chinese Medicine
Outcome results
None listed